Accessibility Menu
BioSyent logo

BioSyent(TSXV) RX

Current PriceCA$14.69
Market CapCA$166.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1988)+1,285%
5 Year+110%
1 Year+29%
1 Month+5%
BioSyent last closing stock price
MetricPriceDate
Last closeCAD 14.692026-07-23
BioSyent stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.31%CAD 14.502026-07-16
1 month+4.63%CAD 14.042026-06-23
3 month-0.01%CAD 14.692026-04-24
Year to date+16.27%CAD 12.632025-12-31
1 year+29.21%CAD 11.372025-07-23
3 year+105.08%CAD 7.162023-07-24
5 year+109.6%CAD 7.012021-07-23
Since inception+1,284.91%CAD 1.051988-09-12

BioSyent Financials at a Glance

Market Cap

CA$166.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$45.98M

Net Income (TTM)

CA$9.04M

EPS (TTM)

CA$0.79

P/E Ratio

18.15

Dividend

CA$0.21

Beta (Volatility)

0.29 (Low)

Price

CA$14.69

Volume

1,800

Open

CA$14.55

Previous Close

CA$14.69

Daily Range

CA$14.54 - CA$14.69

52-Week Range

CA$10.65 - CA$15.80

Estimated Earnings Date

Aug 25, 2026

RX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioSyent

BioSyent Inc. is a Canadian pharmaceutical company focused on acquiring, developing, and selling healthcare products both domestically and internationally. The company specializes in innovative solutions for various medical conditions, particularly in the areas of iron deficiency anemia and women's health.

Products and Services
  • FeraMAX products for iron deficiency anemia treatment and prevention
  • Tibella, a hormone replacement therapy for menopausal symptoms
  • Inofolic, addressing polycystic ovarian syndrome symptoms
Growth Outlook
  • Revenue increased to CAD 13.9 million in Q1 2026, up from CAD 9.7 million in Q4 2025
  • Net income rose to CAD 2.3 million in Q1 2026, reflecting strong operational performance
  • Continued expansion into international markets is expected to drive future growth
Financial Highlights
  • Trailing twelve-month revenue of CAD 49.5 million, showcasing consistent growth
  • Net profit margin of 19.65% indicates strong profitability
  • Dividend yield of 1.43% reflects commitment to returning value to shareholders
BioSyent Inc. has established itself as a key player in the pharmaceutical industry, particularly in niche markets. The company's diverse product portfolio addresses significant health issues, which positions it well for future growth. Recent financial performance demonstrates a robust upward trend, with notable increases in both revenue and net income. The company's strategic focus on international expansion and innovative product development is likely to enhance its market presence and profitability. Investors may find BioSyent Inc. an attractive opportunity within the healthcare sector, given its solid financial foundation and growth potential.
AI Generated • Jul 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

61

CEO

René C. Goehrum

Website

www.biosyent.com

Headquarters

Mississauga, ON L5N 6M1, CA

RX Financials

Key Financial Metrics (TTM)

Gross Margin

74.11%

Operating Margin

25.10%

Net Income Margin

19.65%

Return on Equity

22.05%

Return on Capital

26.74%

Return on Assets

14.46%

Earnings Yield

5.51%

Dividend Yield

1.44%

Payout Ratio

25.54%

Stock Overview

Market Cap

CA$166.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.44M

Volume

1.80K

Avg. Volume

8.04K

Financials (TTM)

Gross Profit

CA$34.08M

Operating Income

CA$11.54M

EBITDA

CA$13.11M

Operating Cash Flow

CA$13.01M

Capital Expenditure

-CA$325.40K

Free Cash Flow

CA$12.69M

Cash & ST Invst.

CA$10.90M

Total Debt

CA$5.25M

BioSyent Performance Analysis

BioSyent annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 27,925,187-2.4%
20232023-12-31CAD 31,590,30213.1%
20242024-12-31CAD 35,030,89710.9%
20252025-12-31CAD 43,051,98322.9%
BioSyent sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-7.3%
Q32025-09-3020.1%
Q42025-12-31-20.9%
Q12026-03-3143.8%
BioSyent annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD 0.44-10.8%
20232023-12-31CAD 0.5322.0%
20242024-12-31CAD 0.6216.0%
20252025-12-31CAD 0.7827.2%
BioSyent sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-10.0%
Q32025-09-3027.8%
Q42025-12-31-21.7%
Q12026-03-3111.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$13.91M

+26.7%

Gross Profit

CA$9.68M

+16.1%

Gross Margin

69.59%

N/A

Market Cap

CA$166.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$2.77M

N/A

Employees

60

N/A

Net Income

CA$2.34M

+1.1%

EBITDA

CA$3.66M

+8.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$10.90M

-37.4%

Total Debt

CA$5.25M

+429.9%

Accounts Receivable

CA$7.55M

+37.8%

Inventory

CA$11.29M

+114.0%

Long Term Debt

CA$813.20K

+3.1%

Short Term Debt

CA$4.43M

+998.5%

Return on Assets

14.46%

N/A

Return on Invested Capital

25.13%

N/A

Free Cash Flow

CA$2.93M

+462.8%

Operating Cash Flow

CA$2.95M

+511.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MDP.TOMedexus Pharmaceuticals Inc.
CA$5.10-0.39%
LOVE.VCannara Biotech Inc.
CA$1.89+6.18%
CRDL.TOCardiol Therapeutics Inc.
CA$1.74-4.40%
ZEN.VZentek Ltd.
CA$0.78-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
NOKNokia
$9.73-0.05%
AALAmerican Airlines Group
$13.56-0.08%
TAT&T
$22.96-0.00%

Questions About RX

What is the current price of BioSyent?

BioSyent is trading at CA$14.69 per share.

What is the 52-week range for BioSyent?

Over the past 52 weeks, BioSyent has traded between CA$10.65 and CA$15.80.

How much debt does BioSyent have?

As of the most recent reporting period, BioSyent reported total debt of CA$5.25M.

How much cash does BioSyent have on hand?

BioSyent reported CA$6.14M in cash and cash equivalents in its most recent financial results.

What is BioSyent’s dividend yield?

BioSyent currently has a dividend yield of 1.44%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services